Clinical Pharmacology and Drug Toxicity Practice Questions

Q: What is the ideal chelating agent in a patient with G6PD deficiency?

DMSA. The correct answer is **DMSA (Succimer)**. In patients with **G6PD deficiency**, the primary concern during chelation therapy is the risk of **oxidative stress**, which can trigger acute hemolysis. G6PD is essential for maintaining the pool of reduced glutathione, which protects erythrocytes from oxidative damage. **Why DMSA is the correct choice:** DMSA (Dimercaptosuccinic acid) is a water-soluble analogue of BAL. It is the preferred chelator in G6PD deficiency because it is **less likely to induce oxidative stress** compared to other agents [1]. It is also the only orally active chelator among the options and has a high therapeutic index, making it safer for pediatric use and patients with enzymatic deficiencies [1]. **Why the other options are incorrect:** * **BAL (British Anti-Lewisite/Dimercaprol):** This is strictly **contraindicated** in G6PD deficiency. BAL is known to cause significant oxidative stress and can precipitate severe **hemolysis** in these patients. It also requires painful intramuscular injections in a peanut oil base. * **DMPS:** While similar to DMSA, it is less commonly used and lacks the extensive safety profile of DMSA regarding G6PD-specific clinical data [1]. * **EDTA (Calcium Disodium):** Primarily used for lead poisoning, EDTA is a polar compound that can cause nephrotoxicity [2]. It does not specifically address the oxidative concerns of G6PD deficiency as effectively as DMSA. **High-Yield Clinical Pearls for NEET-PG:** * **DMSA (Succimer):** Drug of choice for oral chelation in lead, mercury, and arsenic poisoning [1]. * **BAL Contraindications:** G6PD deficiency, severe hepatic failure, and concurrent iron therapy (forms a toxic complex). * **Wilson’s Disease:** Penicillamine is the traditional DOC, but Trientine is preferred if the patient is intolerant. * **Iron Toxicity:** Desferrioxamine (IV) is the DOC; Deferiprone and Deferasirox are oral alternatives.

Q: Which of the following is advocated in dicoumarol poisoning?

Vitamin K. **Explanation:** **Dicoumarol** is a naturally occurring anticoagulant that functions as a competitive inhibitor of **Vitamin K Epoxide Reductase (VKOR)**. Its mechanism of action is identical to Warfarin; it prevents the gamma-carboxylation of Vitamin K-dependent clotting factors (II, VII, IX, and X), leading to a state of functional Vitamin K deficiency and subsequent hemorrhage. **Why Vitamin K is the Correct Answer:** The physiological antidote for dicoumarol (and all coumarin derivatives) is **Vitamin K1 (Phytonadione)**. By providing exogenous Vitamin K, the body can bypass the inhibited VKOR enzyme and resume the synthesis of active clotting factors. In cases of severe life-threatening bleeding, Fresh Frozen Plasma (FFP) or Prothrombin Complex Concentrate (PCC) is administered for immediate effect, followed by Vitamin K for sustained reversal. **Why Other Options are Incorrect:** * **Warfarin (A):** This is another coumarin derivative with the same mechanism as dicoumarol. Administering it would exacerbate the toxicity and bleeding. * **Heparin (B) & LMWH (C):** These are parenteral anticoagulants that activate Antithrombin III. They would further increase the risk of hemorrhage and have no role in reversing the effects of dicoumarol. **High-Yield Clinical Pearls for NEET-PG:** * **Source:** Dicoumarol is found in "sweet clover" and is responsible for "sweet clover disease" in cattle. * **Monitoring:** The effect of dicoumarol/warfarin is monitored using **PT/INR** (Extrinsic pathway). * **Teratogenicity:** Coumarins are teratogenic (Fetal Warfarin Syndrome), causing bone abnormalities (stippled epiphyses) and nasal hypoplasia. * **Antidote Speed:** Vitamin K takes 6–24 hours to work (requires new protein synthesis). For **immediate** reversal, use **PCC** (preferred) or **FFP**.

Q: Hepatotoxicity caused by valproate can be prevented by?

Carnitine. Explanation: Mechanism of Valproate-Induced Hepatotoxicity: Valproate (VPA) is a broad-spectrum antiepileptic that undergoes complex metabolism. A significant portion of its toxicity is attributed to the inhibition of fatty acid beta-oxidation in the mitochondria. VPA and its metabolites (like 4-en-VPA) deplete cellular stores of Carnitine, which is essential for transporting long-chain fatty acids into the mitochondria. This leads to mitochondrial dysfunction, microvesicular steatosis, and hyperammonemia. Supplementation with L-carnitine helps restore the carnitine pool, facilitates the removal of toxic VPA metabolites, and improves mitochondrial function, making it the specific antidote for VPA-induced hepatotoxicity and hyperammonemic encephalopathy. Analysis of Incorrect Options: A. Zinc: While Zinc is used in Wilson’s disease to prevent copper absorption, it has no established role in mitigating valproate toxicity. C. Pyridoxine (Vitamin B6): This is the antidote for Isoniazid (INH) induced peripheral neuropathy and seizures, but it does not prevent VPA-induced liver injury. D. Vitamin K: While Vitamin K is used to manage coagulopathy resulting from liver failure, it does not prevent the underlying hepatotoxic process caused by valproate. High-Yield Clinical Pearls for NEET-PG: Risk Factors: Children under 2 years old on polytherapy are at the highest risk for VPA hepatotoxicity (Fulp-like syndrome). Hyperammonemia: VPA can cause elevated ammonia levels even without deranged liver enzymes; Carnitine is effective here as well. Other Side Effects of VPA: Weight gain, Alopecia (regrowth is curly), Polycystic Ovarian Syndrome (PCOS), and Teratogenicity (Neural tube defects/Spina bifida).

Q: A 61-year-old male with a history of chronic arthritis complains of pronounced tinnitus. He also has some dizziness, with headache. Physical examination reveals some scattered petechiae over the upper extremities. A stool guaiac test result is positive. Which of the following drug toxicities best explains these findings?

Aspirin. ### Explanation The clinical presentation described is a classic case of **Salicylism** (Aspirin toxicity). **1. Why Aspirin is the Correct Answer:** Aspirin (Acetylsalicylic acid) is a non-selective NSAID commonly used for chronic arthritis. Its toxicity manifests through a specific constellation of symptoms: * **Tinnitus and Dizziness:** Tinnitus is the most characteristic early sign of salicylate toxicity, caused by increased labyrinthine pressure and effect on the cochlear hair cells. * **Petechiae and Positive Stool Guaiac:** Aspirin causes irreversible inhibition of COX-1, leading to decreased Thromboxane A2 (TXA2) and impaired platelet aggregation. It also causes direct gastric mucosal irritation, leading to occult GI bleeding (positive stool guaiac). **2. Why Other Options are Incorrect:** * **Penicillin:** Toxicity typically involves hypersensitivity reactions (rashes, anaphylaxis) or, at very high doses, neurotoxicity (seizures), but not tinnitus or bleeding. * **Tetracycline:** Common side effects include GI upset, photosensitivity, and hepatotoxicity (especially in pregnancy), but it does not cause tinnitus or antiplatelet effects. * **Chlorpromazine:** This antipsychotic is associated with extrapyramidal symptoms, sedation, and cholestatic jaundice, but not the auditory or hemorrhagic symptoms seen here. **3. NEET-PG High-Yield Pearls:** * **Acid-Base Balance:** Early aspirin toxicity causes **Respiratory Alkalosis** (direct stimulation of the respiratory center). Late/Severe toxicity causes **Mixed Respiratory Alkalosis and Metabolic Acidosis** (Anion Gap). * **Management:** Treatment involves **Urinary Alkalinization** (using Sodium Bicarbonate) to enhance salicylate excretion (ion trapping). * **Triad of Salicylism:** Tinnitus, Headache, and Mental Confusion.

Q: Phase IV of clinical trials collect information specifically about which of the following?

Drug toxicity. **Explanation:** **Phase IV Clinical Trials**, also known as **Post-Marketing Surveillance (PMS)**, are conducted after a drug has been approved and launched in the market. **Why "Drug Toxicity" is Correct:** While Phase I, II, and III trials involve a limited number of selected participants (usually <3,000), Phase IV monitors the drug in the general population (millions of users). This allows for the detection of **rare, long-term, or idiosyncratic adverse drug reactions (ADRs)** and chronic toxicities that were not evident during shorter, smaller pre-marketing trials. For example, the cardiotoxicity of Rofecoxib was identified only during Phase IV, leading to its withdrawal. **Why Other Options are Incorrect:** * **A. Drug Efficacy:** This is primarily established in **Phase III** (comparative trials) and **Phase II** (proof of concept). Phase IV looks at "effectiveness" in real-world settings, but its primary regulatory purpose is safety monitoring. * **B. Drug Potency:** This is a pharmacodynamic property determined during **pre-clinical animal studies** and early human trials; it is not the focus of Phase IV. * **C. Pharmacokinetics:** Basic PK parameters (Absorption, Distribution, Metabolism, Excretion) are established in **Phase I** (healthy volunteers). **High-Yield Clinical Pearls for NEET-PG:** * **Phase 0:** Microdosing studies to determine PK parameters (Human microdosing). * **Phase I:** Safety and Tolerability (usually in healthy volunteers, except for oncology drugs). * **Phase II:** Therapeutic dose-finding and efficacy (Small group of patients). * **Phase III:** Definitive assessment of efficacy and safety (Large multicentric RCTs). * **Black Box Warning:** Often added to a drug label as a result of Phase IV data.

Q: What is the primary purpose of pharmacovigilance?

To monitor adverse effects of drugs. **Explanation:** Pharmacovigilance (PV) is defined by the WHO as the science and activities relating to the **detection, assessment, understanding, and prevention of adverse effects** or any other drug-related problems. Its primary goal is to ensure patient safety by identifying previously unrecognized adverse drug reactions (ADRs) after a drug has been released into the market (Phase IV clinical trials). **Analysis of Options:** * **Option C (Correct):** The core mandate of pharmacovigilance is the continuous monitoring of the safety profile of drugs. Since clinical trials (Phases I-III) involve limited populations, rare or long-term adverse effects are often only discovered through post-marketing surveillance. * **Option A:** Regulating pharmaceutical companies is the role of national regulatory authorities (like the CDSCO in India or the FDA in the USA), not the specific process of pharmacovigilance. * **Option B:** While efficacy is monitored during clinical trials, pharmacovigilance focuses specifically on *safety* rather than how well the drug works (efficacy) or its chemical strength (potency). * **Option D:** Ethical drug practices are governed by Bioethics committees and Good Clinical Practice (GCP) guidelines. **High-Yield Clinical Pearls for NEET-PG:** * **Phase IV Clinical Trial:** This is synonymous with post-marketing surveillance and is the stage where pharmacovigilance is most active. * **Pharmacovigilance Programme of India (PvPI):** Launched in 2010; the National Coordinating Centre is the Indian Pharmacopoeia Commission (IPC), Ghaziabad. * **Uppsala Monitoring Centre (UMC):** Located in Sweden, it is the WHO collaborating centre for international drug monitoring. * **Spontaneous Reporting:** This is the most common method used in pharmacovigilance to identify new ADRs.

Q: Which of the following is an antidote to acetaminophen poisoning?

N-acetyl cysteine. **Explanation:** **1. Why N-acetyl cysteine (NAC) is correct:** Acetaminophen (Paracetamol) is primarily metabolized via glucuronidation and sulfation. However, a small portion is converted by **CYP2E1** into a highly reactive toxic metabolite called **NAPQI** (*N-acetyl-p-benzoquinone imine*). In overdose, glutathione stores are depleted, leading to NAPQI-induced hepatic necrosis. **N-acetyl cysteine (NAC)** acts as an antidote by: * Replenishing **glutathione** stores. * Acting as a glutathione substitute to directly conjugate and detoxify NAPQI. * It is most effective when administered within 8–10 hours of ingestion. **2. Why the other options are incorrect:** * **Atropine:** A muscarinic antagonist used for **organophosphate poisoning** or symptomatic bradycardia. * **Flumazenil:** A competitive benzodiazepine receptor antagonist used to reverse **benzodiazepine overdose**. * **Naloxone:** A pure opioid antagonist used for the emergency reversal of **opioid toxicity** (respiratory depression). **3. High-Yield Clinical Pearls for NEET-PG:** * **Rumack-Matthew Nomogram:** Used to determine the need for NAC treatment based on plasma acetaminophen levels vs. time since ingestion (only valid for single acute ingestions). * **Toxicity Marker:** NAPQI is the toxic metabolite; the liver is the primary organ affected (Centrilobular necrosis). * **NAC Administration:** Can be given IV or orally. The oral protocol typically lasts 72 hours, while the IV protocol (Acetadote) is 21 hours. * **Drug of Choice:** NAC is also used as a mucolytic in cystic fibrosis and to prevent contrast-induced nephropathy.

Q: A 41-year-old woman with glaucoma is treated with acetazolamide. Several weeks later, she has an arterial pH of 7.34, an arterial PCO2 of 29 mm Hg, and a plasma HCO3- of 15 mEq/L. Which of the following abnormalities has this woman most likely developed?

Metabolic acidosis. ### **Explanation** **1. Why Metabolic Acidosis is Correct:** Acetazolamide is a **carbonic anhydrase inhibitor** that acts on the proximal convoluted tubule of the kidney. It inhibits the reabsorption of sodium bicarbonate ($NaHCO_3$), leading to "bicarbonate wasting" in the urine. * **Mechanism:** By preventing the conversion of $H_2CO_3$ to $H_2O$ and $CO_2$ in the lumen, it causes a significant loss of $HCO_3^-$ in the urine. * **Laboratory Findings:** The patient’s $HCO_3^-$ is low (15 mEq/L; Normal: 22–28), and the pH is acidic (7.34; Normal: 7.35–7.45). This confirms a **primary metabolic acidosis**. * **Compensation:** The low $PCO_2$ (29 mm Hg; Normal: 35–45) indicates that the lungs are compensating by "blowing off" $CO_2$ (respiratory compensation), but the primary insult remains metabolic. **2. Why Other Options are Wrong:** * **Metabolic Alkalosis:** This would present with an elevated pH (>7.45) and elevated $HCO_3^-$. Acetazolamide causes the opposite by depleting bicarbonate. * **Mixed Acidosis:** This would require both a low $HCO_3^-$ (metabolic) and a high $PCO_2$ (respiratory). Here, the $PCO_2$ is low, indicating appropriate compensation, not a primary respiratory disorder. * **Mixed Alkalosis:** This would involve an elevated pH with both high $HCO_3^-$ and low $PCO_2$. **3. NEET-PG High-Yield Pearls:** * **Type of Acidosis:** Acetazolamide causes a **Normal Anion Gap Metabolic Acidosis (NAGMA)**, specifically a Type 2 Renal Tubular Acidosis (RTA). * **Clinical Uses:** Glaucoma (decreases aqueous humor production), Altitude Sickness (induces metabolic acidosis to drive ventilation), and Idiopathic Intracranial Hypertension. * **Side Effects:** Hypokalemia, paresthesias, and sulfa-drug allergy cross-reactivity. * **Mnemonic for NAGMA:** **HARDUPS** (Hyperalimentation, Acetazolamide, Renal tubular acidosis, Diarrhea, Ureteroenteric fistula, Pancreatic fistula, Spironolactone).

Question 1

What is the ideal chelating agent in a patient with G6PD deficiency?

Accepted Answer

DMSA

Answer

DMPS

Answer

EDTA

Answer

BAL

Question 2

Which of the following is advocated in dicoumarol poisoning?

Accepted Answer

Vitamin K

Answer

Warfarin

Answer

Heparin

Answer

LMWH

Question 3

Hepatotoxicity caused by valproate can be prevented by?

Accepted Answer

Carnitine

Answer

Zinc

Answer

Pyridoxine

Answer

Vitamin K

Question 4

A 61-year-old male with a history of chronic arthritis complains of pronounced tinnitus. He also has some dizziness, with headache. Physical examination reveals some scattered petechiae over the upper extremities. A stool guaiac test result is positive. Which of the following drug toxicities best explains these findings?

Accepted Answer

Aspirin

Answer

Penicillin

Answer

Tetracycline

Answer

Chlorpromazine

Question 5

Phase IV of clinical trials collect information specifically about which of the following?

Accepted Answer

Drug toxicity

Answer

Drug efficacy

Answer

Drug potency

Answer

Pharmacokinetics of the drug

Question 6

Which chelating agent for copper, mercury, and lead poisoning is administered orally?

Accepted Answer

Penicillamine

Answer

BAL

Answer

EDTA

Answer

Succimer

Question 7

What is the primary purpose of pharmacovigilance?

Accepted Answer

To monitor adverse effects of drugs

Answer

To regulate pharmacy companies

Answer

To monitor drug potency and efficacy

Answer

To ensure ethical drug practices

Question 8

Which of the following is an antidote to acetaminophen poisoning?

Accepted Answer

N-acetyl cysteine

Answer

Atropine

Answer

Flumazenil

Answer

Naloxone

Question 9

Which of the following drugs cannot be removed by dialysis?

Accepted Answer

Furosemide

Answer

Propranolol

Answer

Digoxin

Answer

Morphine

Question 10

A 41-year-old woman with glaucoma is treated with acetazolamide. Several weeks later, she has an arterial pH of 7.34, an arterial PCO2 of 29 mm Hg, and a plasma HCO3- of 15 mEq/L. Which of the following abnormalities has this woman most likely developed?

Accepted Answer

Metabolic acidosis

Answer

Metabolic alkalosis

Answer

Mixed acidosis

Answer

Mixed alkalosis

Clinical Pharmacology and Drug Toxicity — MCQs

Clinical Pharmacology and Drug Toxicity — MCQs

On this page

Practice by Chapter

Want unlimited practice?